{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:18:22Z","timestamp":1793276302151,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40265-013-0069-4","type":"journal-article","created":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T14:19:49Z","timestamp":1370009989000},"page":"919-934","source":"Crossref","is-referenced-by-count":717,"title":["Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity"],"prefix":"10.1007","volume":"73","author":[{"given":"Richard J.","family":"Hamill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,1]]},"reference":[{"issue":"8","key":"69_CR1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"DP Kontoyiannis","year":"2010","unstructured":"Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 1002\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091\u2013100.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"69_CR2","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","volume":"17","author":"BJ Park","year":"2011","unstructured":"Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-aspergillus mold infections in transplant recipients, United States, 2001\u20132006. Emerg Infect Dis. 2011;17(10):1855\u201364.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"69_CR3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2012.06.012","volume":"73","author":"N Azie","year":"2012","unstructured":"Azie N, Neofytos D, Pfaller M, et al. The PATH (Prospective Antifungal Therapy) Alliance\u00ae registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73(4):293\u2013300.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"69_CR4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","volume":"12","author":"HA Gallis","year":"1990","unstructured":"Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12(2):308\u201329.","journal-title":"Rev Infect Dis"},{"issue":"1","key":"69_CR5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01575125","volume":"16","author":"KM Wasan","year":"1997","unstructured":"Wasan KM, Lopez-Berestein G. Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis. 1997;16(1):81\u201392.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"69_CR6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","volume":"27","author":"A Wong-Beringer","year":"1998","unstructured":"Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998;27(3):603\u201318.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"69_CR7","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/jac\/dkl141","volume":"57","author":"H Vogelsinger","year":"2006","unstructured":"Vogelsinger H, Weiler S, Djanani A, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006;57(6):1153\u201360.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"69_CR8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","volume":"46","author":"I Bekersky","year":"2002","unstructured":"Bekersky I, Fielding RM, Dressler DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother. 2002;46(3):834\u201340.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0079-6468(08)70148-6","volume":"14","author":"SM Hammond","year":"1977","unstructured":"Hammond SM. Biological activity of polyene antibiotics. Prog Med Chem. 1977;14:105\u201379.","journal-title":"Prog Med Chem"},{"issue":"7","key":"69_CR10","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/JCM.37.7.2343-2345.1999","volume":"37","author":"DA Sutton","year":"1999","unstructured":"Sutton DA, Sanche SE, Revankar SG, et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol. 1999;37(7):2343\u20135.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"69_CR11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jac\/39.2.163","volume":"39","author":"I Pujol","year":"1997","unstructured":"Pujol I, Gurarro J, Gen\u00e9 J, et al. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother. 1997;39(2):163\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"69_CR12","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.05910-11","volume":"56","author":"M Lackner","year":"2012","unstructured":"Lackner M, de Hoog GS, Verweij PE, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56(5):2635\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"69_CR13","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/JCM.28.7.1616-1622.1990","volume":"28","author":"TJ Walsh","year":"1990","unstructured":"Walsh TJ, Melcher GP, Rinaldi MG, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990;28(7):1616\u201322.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"69_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11046-008-9136-x","volume":"166","author":"TC Chagas-Neto","year":"2008","unstructured":"Chagas-Neto TC, Chaves GM, Colombo AL. Update on the genus Trichosporon. Mycopathologia. 2008;166(3):121\u201332.","journal-title":"Mycopathologia"},{"issue":"4","key":"69_CR15","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1128\/JCM.01614-08","volume":"47","author":"TC Chagas-Neto","year":"2009","unstructured":"Chagas-Neto TC, Chaves GM, Melo ASA, et al. Bloodstream infections due to Trichosporon spp.: species distribution, Trichosoporon ashahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing. J Clin Microbiol. 2009;47(4):1074\u201381.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"69_CR16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1128\/AAC.43.4.836","volume":"43","author":"SA Yoon","year":"1999","unstructured":"Yoon SA, Vazquez JA, Steffan PE, et al. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother. 1999;43(4):836\u201345.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"69_CR17","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1128\/AAC.41.6.1392","volume":"41","author":"ME Klepser","year":"1997","unstructured":"Klepser ME, Wolfe EJ, Jones RN, et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother. 1997;41(6):1392\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"39","key":"69_CR18","doi-asserted-by":"crossref","first-page":"37561","DOI":"10.1074\/jbc.M306137200","volume":"278","author":"K Sau","year":"2003","unstructured":"Sau K, Mambula SS, Latz E, et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem. 2003;278(39):37561\u20138.","journal-title":"J Biol Chem"},{"issue":"2","key":"69_CR19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1086\/589290","volume":"47","author":"R Ben-Ami","year":"2008","unstructured":"Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47(2):226\u201335.","journal-title":"Clin Infect Dis"},{"issue":"11\u201312","key":"69_CR20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1439-0507.1995.tb00020.x","volume":"38","author":"M Arning","year":"1995","unstructured":"Arning M, Kliche KO, Heer-Sonderhoff AH, et al. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses. 1995;38(11\u201312):459\u201365.","journal-title":"Mycoses"},{"issue":"6","key":"69_CR21","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/314495","volume":"178","author":"PD Rogers","year":"1998","unstructured":"Rogers PD, Jenkins JK, Chapman SW, et al. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis. 1998;178(6):1726\u201333.","journal-title":"J Infect Dis"},{"issue":"5","key":"69_CR22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1592\/phco.23.5.572.32209","volume":"23","author":"JD Cleary","year":"2003","unstructured":"Cleary JD, Rogers PD, Chapman SW. Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy. 2003;23(5):572\u20138.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"69_CR23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/clinids\/20.4.755","volume":"20","author":"SD Goodwin","year":"1995","unstructured":"Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regiments for adverse events related to infusion of amphotericin B. Clin Infect Dis. 1995;20(4):755\u201361.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"69_CR24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1681\/ASN.V62154","volume":"6","author":"BP Sawaya","year":"1995","unstructured":"Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6(2):154\u201364.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"69_CR25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0005-2736(82)90103-1","volume":"685","author":"JD Readio","year":"1982","unstructured":"Readio JD, Bittman R. Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols. Biochim Biophys Acta. 1982;685(2):219\u201334.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"69_CR26","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/clinids\/23.5.1126","volume":"23","author":"KM Wasan","year":"1996","unstructured":"Wasan KM, Lopez-Berestein G. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis. 1996;23(5):1126\u201338.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"69_CR27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.38.2.223","volume":"38","author":"KM Wasan","year":"1994","unstructured":"Wasan KM, Rosenblum MG, Cheung L, et al. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother. 1994;38(2):223\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"69_CR28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0003-2697(83)90700-5","volume":"135","author":"M Krieger","year":"1983","unstructured":"Krieger M. The use of amphotericin B to detect inhibitors of cellular cholesterol biosynthesis. Anal Biochem. 1983;135(2):383\u201391.","journal-title":"Anal Biochem"},{"issue":"12","key":"69_CR29","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","volume":"29","author":"JR Wingard","year":"1999","unstructured":"Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999;29(12):1402\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"69_CR30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","volume":"32","author":"DW Bates","year":"2001","unstructured":"Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32(3):686\u201393.","journal-title":"Clin Infect Dis"},{"issue":"35","key":"69_CR31","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1086\/344468","volume":"15","author":"S Harbarth","year":"2002","unstructured":"Harbarth S, Burke JP, Lloyd JF, et al. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis. 2002;15(35):e120\u20137.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"69_CR32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-199223040-00004","volume":"23","author":"R Janknegt","year":"1992","unstructured":"Janknegt R, de Marie S, Bakker-Woudenberg IA, et al. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet. 1992;23(4):279\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 2","key":"69_CR33","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","volume":"22","author":"JW Hiemenz","year":"1996","unstructured":"Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996;22(Suppl 2):S133\u201344.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"69_CR34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0145-2126(96)00075-6","volume":"23","author":"J Mehta","year":"1997","unstructured":"Mehta J. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Leukemia Res. 1997;23(5):183\u20138.","journal-title":"Leukemia Res"},{"issue":"2\u20133","key":"69_CR35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0169-409X(96)00496-6","volume":"24","author":"AM Hillery","year":"1997","unstructured":"Hillery AM. Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv Drug Del Rev. 1997;24(2\u20133):345\u201363.","journal-title":"Adv Drug Del Rev"},{"issue":"3","key":"69_CR36","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1592\/phco.19.4.306.30934","volume":"19","author":"D Slain","year":"1999","unstructured":"Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy. 1999;19(3):306\u201323.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"69_CR37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0924-8579(00)00341-1","volume":"17","author":"IM Hann","year":"2001","unstructured":"Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents. 2001;17(3):161\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl S1","key":"69_CR38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.suppl_1.31","volume":"49","author":"B Dupont","year":"2002","unstructured":"Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002;49(suppl S1):31\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"69_CR39","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/14656566.4.8.1277","volume":"4","author":"R Herbrecht","year":"2003","unstructured":"Herbrecht R, Natarajan-Am\u00e9 S, Nivoix Y, et al. The lipid formulations of amphotericin B. Expert Opin Pharmacother. 2003;4(8):1277\u201387.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 4","key":"69_CR40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1469-0691.2008.01979.x","volume":"14","author":"JP Adler-Moore","year":"2008","unstructured":"Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect. 2008;14(Suppl 4):25\u201336.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"69_CR41","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/js990101z","volume":"88","author":"AL Kennedy","year":"1999","unstructured":"Kennedy AL, Wasan KM. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content. J Pharm Sci. 1999;88(11):1149\u201355.","journal-title":"J Pharm Sci"},{"issue":"4","key":"69_CR42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/AAC.38.4.713","volume":"38","author":"JW Lee","year":"1994","unstructured":"Lee JW. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother. 1994;38(4):713\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"69_CR43","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1749-6632.1985.tb18416.x","volume":"446","author":"RL Juliano","year":"1985","unstructured":"Juliano RL, Lopez-Berestein G, Hopfer R, et al. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann N Y Acad Sci. 1985;446(1):390\u2013402.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"69_CR44","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00933-12","volume":"56","author":"WW Hope","year":"2013","unstructured":"Hope WW, Goodwin J, Felton TW, et al. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational dosing of innovative regimens. Antimicrob Agents Chemother. 2013;56(10):5303\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"69_CR45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jac\/34.6.975","volume":"24","author":"A Louie","year":"1994","unstructured":"Louie A, Baltch AL, Fanke MA, et al. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother. 1994;24(6):975\u201387.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"69_CR46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jac\/dkh542","volume":"55","author":"S Bellocchio","year":"2005","unstructured":"Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signaling from TLR-2 to TLR-4. J Antimicrob Chemother. 2005;55(2):214\u201322.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"69_CR47","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1128\/AAC.49.4.1397-1403.2005","volume":"49","author":"M Simitsopoulou","year":"2005","unstructured":"Simitsopoulou M, Roilides E, Dotis J, et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother. 2005;49(4):1397\u2013403.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"69_CR48","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1185\/030079904125003179","volume":"20","author":"R Martino","year":"2004","unstructured":"Martino R. Efficacy, safety and cost-effectiveness of amphotericin B lipid complex (ABLC): a review of the literature. Curr Med Res Opin. 2004;20(4):485\u2013504.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"69_CR49","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/AAC.41.10.2201","volume":"41","author":"A Adedoyin","year":"1997","unstructured":"Adedoyin A, Bernardo JF, Swenson CE, et al. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother. 1997;41(10):2201\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"69_CR50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.42.4.767","volume":"32","author":"CE Swenson","year":"1998","unstructured":"Swenson CE, Perkins WR, Roberts P, et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother. 1998;32(4):767\u201371.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"69_CR51","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1128\/AAC.45.11.3231-3233.2001","volume":"45","author":"M Gottfredsson","year":"2001","unstructured":"Gottfredsson M, Jessup CJ, Cox GM, et al. Fungal phospholipase activity and susceptibility to lipid preparations of amphotericin B. Antimicrob Agents Chemother. 2001;45(11):3231\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"69_CR52","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/j.1552-4604.1998.tb04464.x","volume":"38","author":"GW Boswell","year":"1998","unstructured":"Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol. 1998;38(7):583\u201392.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"69_CR53","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003495-200969030-00010","volume":"69","author":"MD Moen","year":"2009","unstructured":"Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B. A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009;69(3):361\u201392.","journal-title":"Drugs"},{"issue":"3","key":"69_CR54","first-page":"151","volume":"3","author":"JP Adler-Moore","year":"1993","unstructured":"Adler-Moore JP, Fujii G, Lee MA. In vitro and in vivo interactions of AmBisome with pathogenic fungi. J Liposome Res. 1993;3(3):151\u20136.","journal-title":"J Liposome Res"},{"issue":"3","key":"69_CR55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","volume":"3","author":"JP Adler-Moore","year":"1993","unstructured":"Adler-Moore JP, Proffitt T. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res. 1993;3(3):429\u201350.","journal-title":"J Liposome Res"},{"issue":"12","key":"69_CR56","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","volume":"45","author":"TJ Walsh","year":"2001","unstructured":"Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45(12):3487\u201396.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"69_CR57","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","volume":"182","author":"AH Groll","year":"2000","unstructured":"Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182(1):274\u201382.","journal-title":"J Infect Dis"},{"issue":"1","key":"69_CR58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0378-5173(91)90249-N","volume":"75","author":"LS Guo","year":"1991","unstructured":"Guo LS, Fielding RM, Lasic DD, et al. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int J Pharm. 1991;75(1):45\u201354.","journal-title":"Int J Pharm"},{"issue":"Suppl 1","key":"69_CR59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000048466","volume":"45","author":"PK Working","year":"1999","unstructured":"Working PK, Amphotericin B. Colloidal dispersion. A pre-clinical review. Chemotherapy. 1999;45(Suppl 1):15\u201326.","journal-title":"Chemotherapy"},{"issue":"5","key":"69_CR60","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/infdis\/173.5.1208","volume":"173","author":"RA Bowden","year":"1996","unstructured":"Bowden RA, Cays M, Gooley T, et al. Phase 1 study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplantation. J Infect Dis. 1996;173(5):1208\u201315.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"69_CR61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000048472","volume":"45","author":"R Herbrecht","year":"1999","unstructured":"Herbrecht R, Letscher V, Andres E, et al. Safety and efficacy of amphotericin B colloidal dispersion. Chemotherapy. 1999;45(Suppl 1):67\u201376.","journal-title":"Chemotherapy"},{"issue":"8","key":"69_CR62","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1702243","volume":"25","author":"GJ Timmers","year":"2000","unstructured":"Timmers GJ, Zweegman S, Simoons-Smit AM, et al. Amphotericin B colloidal dispersion (Amphocil) versus fluconazole for the prevention of fungal infection in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant. 2000;25(8):879\u201384.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"69_CR63","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0609.2004.00239.x","volume":"72","author":"M Subir\u00e0","year":"2004","unstructured":"Subir\u00e0 M, Martino R, G\u00f3mez L, et al. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies\u2014a randomized, controlled trial. Eur J Haematol. 2004;72(5):342\u20137.","journal-title":"Eur J Haematol"},{"issue":"3","key":"69_CR64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","volume":"98","author":"HG Prentice","year":"1997","unstructured":"Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98(3):711\u20138.","journal-title":"Br J Haematol"},{"issue":"10","key":"69_CR65","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","volume":"340","author":"TJ Walsh","year":"1999","unstructured":"Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340(10):764\u201371.","journal-title":"N Engl J Med"},{"issue":"5","key":"69_CR66","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","volume":"31","author":"JR Wingard","year":"2000","unstructured":"Wingard JR, White MH, Anaissie E, L Amph\/ABLC Collaborative Study Group, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000;31(5):1155\u201363.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"69_CR67","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","volume":"27","author":"MH White","year":"1998","unstructured":"White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27(2):296\u2013302.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"69_CR68","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","volume":"35","author":"R Bowden","year":"2002","unstructured":"Bowden R, Chandresekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35(2):359\u201366.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"69_CR69","first-page":"635","volume":"24","author":"MH White","year":"1997","unstructured":"White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997;24(4):635\u201342.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"69_CR70","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, for the AmBiLoad Trial Study Group, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis. 2007;44(10):1289\u2013306.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"69_CR71","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","volume":"103","author":"AC Leenders","year":"1998","unstructured":"Leenders AC, Daenen S, Jansen RLH, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103(3):205\u201312.","journal-title":"Br J Haematol"},{"issue":"5\u20136","key":"69_CR72","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10428190109097650","volume":"40","author":"RV Fleming","year":"2001","unstructured":"Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leukemia Lymphoma. 2001;40(5\u20136):511\u201320.","journal-title":"Leukemia Lymphoma"},{"issue":"6","key":"69_CR73","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/jac\/dkh003","volume":"52","author":"MT Mart\u00edn","year":"2003","unstructured":"Mart\u00edn MT, Gavald\u00e0 J, L\u00f3pez P, et al. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. J Antimicrob Chemother. 2003;52(6):1032\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"69_CR74","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1469-0691.2005.01262.x","volume":"11","author":"J Gavald\u00e0","year":"2005","unstructured":"Gavald\u00e0 J, Mart\u00edn T, L\u00f3pez P, et al. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis. Clin Microbiol Infect. 2005;11(12):999\u20131004.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"69_CR75","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","volume":"137","author":"PC Johnson","year":"2002","unstructured":"Johnson PC, Wheat LJ, Cloud GA, for the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105\u20139.","journal-title":"Ann Intern Med"},{"issue":"2","key":"69_CR76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","volume":"22","author":"PK Sharkey","year":"1996","unstructured":"Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22(2):315\u201321.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"69_CR77","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","volume":"11","author":"AC Leenders","year":"1997","unstructured":"Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11(12):1463\u201371.","journal-title":"AIDS"},{"issue":"2","key":"69_CR78","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","volume":"51","author":"RJ Hamill","year":"2010","unstructured":"Hamill RJ, Sobel JD, El-Sadr W, the AmBisome Cryptococcal Meningitis Study Group, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51(2):225\u201332.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"69_CR79","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","volume":"17","author":"M Boer den","year":"2011","unstructured":"den Boer M, Argaw D, Jannin J, et al. Leishmaniasis impact and treatment access. Clin Microbiol Infect. 2011;17(10):1471\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"69_CR80","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","volume":"43","author":"C Bern","year":"2006","unstructured":"Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006;43(7):917\u201324.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"69_CR81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","volume":"28","author":"AUS Meyerhoff","year":"1999","unstructured":"Meyerhoff AUS. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999;28(1):42\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"69_CR82","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","volume":"362","author":"S Sundar","year":"2010","unstructured":"Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362(6):504\u201312.","journal-title":"N Engl J Med"},{"issue":"5","key":"69_CR83","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","volume":"25","author":"JP Barrett","year":"2003","unstructured":"Barrett JP, Vardulaki KA, Conlon C, The Amphotericin B Systematic Review Study Group, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003;25(5):1295\u2013320.","journal-title":"Clin Ther"},{"key":"69_CR84","doi-asserted-by":"crossref","unstructured":"Johansen HK, G\u00f8tzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev. 2000;(3):CD000969. doi: 10.1002\/14651858.CD000969 .","DOI":"10.1002\/14651858.CD000969"},{"issue":"2","key":"69_CR85","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10096-005-0080-0","volume":"25","author":"SB Girois","year":"2006","unstructured":"Girois SB, Chapuis F, Decullier E, et al. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2006;25(2):138\u201349.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"69_CR86","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0b013e3181e9441b","volume":"89","author":"A Safdar","year":"2010","unstructured":"Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine. 2010;89(4):236\u201344.","journal-title":"Medicine"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0069-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0069-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0069-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T13:53:45Z","timestamp":1645624425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0069-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":86,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0069-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}